Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis

The reactivation of latent Leishmania infection in chronic diseases and immunocompromised hosts is a broad and heterogeneous field in medicine and infectious diseases. We reported one of the first cases of Visceral Leishmaniasis occurring in a Caucasian middle-aged man living in an endemic country (...

Descripción completa

Detalles Bibliográficos
Autores principales: Lupia, Tommaso, Corcione, Silvia, Fornari, Valentina, Rizzello, Barbara, Bosio, Roberta, Brusa, Maria Teresa, De Rosa, Francesco Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609957/
https://www.ncbi.nlm.nih.gov/pubmed/36288060
http://dx.doi.org/10.3390/tropicalmed7100319
_version_ 1784819150045052928
author Lupia, Tommaso
Corcione, Silvia
Fornari, Valentina
Rizzello, Barbara
Bosio, Roberta
Brusa, Maria Teresa
De Rosa, Francesco Giuseppe
author_facet Lupia, Tommaso
Corcione, Silvia
Fornari, Valentina
Rizzello, Barbara
Bosio, Roberta
Brusa, Maria Teresa
De Rosa, Francesco Giuseppe
author_sort Lupia, Tommaso
collection PubMed
description The reactivation of latent Leishmania infection in chronic diseases and immunocompromised hosts is a broad and heterogeneous field in medicine and infectious diseases. We reported one of the first cases of Visceral Leishmaniasis occurring in a Caucasian middle-aged man living in an endemic country (Italy) for Leishmania infantum infection following secukinumab treatment for psoriatic arthritis. The patient was cured with a Liposomal Amphotericin B (L-AmB, 3 mg/Kg on days 1–5, followed by a dose on days 10, 17, 24, 31 and 38) regimen, after which his anti-interleukin 17 treatment was restarted—without recurrence in the follow-up.
format Online
Article
Text
id pubmed-9609957
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96099572022-10-28 Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis Lupia, Tommaso Corcione, Silvia Fornari, Valentina Rizzello, Barbara Bosio, Roberta Brusa, Maria Teresa De Rosa, Francesco Giuseppe Trop Med Infect Dis Case Report The reactivation of latent Leishmania infection in chronic diseases and immunocompromised hosts is a broad and heterogeneous field in medicine and infectious diseases. We reported one of the first cases of Visceral Leishmaniasis occurring in a Caucasian middle-aged man living in an endemic country (Italy) for Leishmania infantum infection following secukinumab treatment for psoriatic arthritis. The patient was cured with a Liposomal Amphotericin B (L-AmB, 3 mg/Kg on days 1–5, followed by a dose on days 10, 17, 24, 31 and 38) regimen, after which his anti-interleukin 17 treatment was restarted—without recurrence in the follow-up. MDPI 2022-10-20 /pmc/articles/PMC9609957/ /pubmed/36288060 http://dx.doi.org/10.3390/tropicalmed7100319 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Lupia, Tommaso
Corcione, Silvia
Fornari, Valentina
Rizzello, Barbara
Bosio, Roberta
Brusa, Maria Teresa
De Rosa, Francesco Giuseppe
Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis
title Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis
title_full Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis
title_fullStr Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis
title_full_unstemmed Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis
title_short Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis
title_sort visceral leishmaniasis after anti-interleukin 17a (il-17a) therapy in a patient affected by psoriatic arthritis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609957/
https://www.ncbi.nlm.nih.gov/pubmed/36288060
http://dx.doi.org/10.3390/tropicalmed7100319
work_keys_str_mv AT lupiatommaso visceralleishmaniasisafterantiinterleukin17ail17atherapyinapatientaffectedbypsoriaticarthritis
AT corcionesilvia visceralleishmaniasisafterantiinterleukin17ail17atherapyinapatientaffectedbypsoriaticarthritis
AT fornarivalentina visceralleishmaniasisafterantiinterleukin17ail17atherapyinapatientaffectedbypsoriaticarthritis
AT rizzellobarbara visceralleishmaniasisafterantiinterleukin17ail17atherapyinapatientaffectedbypsoriaticarthritis
AT bosioroberta visceralleishmaniasisafterantiinterleukin17ail17atherapyinapatientaffectedbypsoriaticarthritis
AT brusamariateresa visceralleishmaniasisafterantiinterleukin17ail17atherapyinapatientaffectedbypsoriaticarthritis
AT derosafrancescogiuseppe visceralleishmaniasisafterantiinterleukin17ail17atherapyinapatientaffectedbypsoriaticarthritis

Ejemplares similares